Genmab A (GMAB) Change in Receivables (2019 - 2026)

Genmab A has reported Change in Receivables for 5 years, with the latest figure at $158.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 27.42% year-over-year to $158.0 million; the trailing twelve-month figure through Mar 2026 stood at -$141.0 million (up 68.67% YoY), and the FY2025 full-year result was -$166.0 million, down 117.98% from the prior year.
• Change in Receivables for Q1 2026 stood at $158.0 million, down from $1.0 billion in the prior quarter.
• The five-year high for Change in Receivables was $1.0 billion in Q3 2025, with the low at -$230.0 million in Q4 2024.
• Historically, Change in Receivables has averaged $223.9 million across 3 years, with a median of $81.5 million in 2024.
• Annual changes were most pronounced in 2025 — Change in Receivables surged 760.93% — and 2026, when it rose 27.42%.
• Genmab A's Change in Receivables stood at -$230.0 million in 2024, then jumped by 554.78% to $1.0 billion in 2025, then slumped by 84.89% to $158.0 million in 2026.
• The last three Change in Receivables figures came in at $158.0 million (Q1 2026), $1.0 billion (Q3 2025), and $998.0 million (Q2 2025), per Business Quant data.